Nektar Therapeutics (NKTR) Current Deferred Revenue (2010 - 2020)
Nektar Therapeutics (NKTR) posted quarterly Current Deferred Revenue of $91000.0 for Q4 2020, down 98.87% year-over-year from $8.1 million in Q1 2020, and down 96.97% quarter-over-quarter from $3.0 million in Q3 2020.
Nektar Therapeutics (NKTR) Current Deferred Revenue (2010 - 2020) Analysis & Trends
Nektar Therapeutics' Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $91000.0 for Q4 2020.
- In Q4 2020, Current Deferred Revenue fell 98.87% year-over-year to $91000.0; the TTM figure through Dec 2020 stood at $91000.0 (down 98.87% YoY), while the FY2020 annual figure was $91000.0, down 98.87% from the prior year.
- Current Deferred Revenue for Q4 2020 stood at $91000.0, down from $3.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $32.3 million in Q1 2018, with the low at $91000.0 in Q4 2020.
- The 5-year median for Current Deferred Revenue is $16.6 million (2016), against an average of $15.5 million.
- The sharpest annual moves came in 2017 and 2020: Current Deferred Revenue jumped 80.77% in 2017, then slumped 98.87% in 2020.
- Nektar Therapeutics' Current Deferred Revenue stood at $14.4 million in 2016, then surged by 32.03% to $18.9 million in 2017, then jumped by 30.01% to $24.6 million in 2018, then sank by 67.24% to $8.1 million in 2019, then plunged by 98.87% to $91000.0 in 2020.
- Business Quant data shows NKTR's Current Deferred Revenue at $91000.0 in Q4 2020, $3.0 million in Q3 2020, and $1.8 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 91,000.00 |
| Sep 30, 2020 | 3.00 Mn |
| Jun 30, 2020 | 1.76 Mn |
| Mar 31, 2020 | 5.56 Mn |
| Dec 31, 2019 | 8.07 Mn |
| Sep 30, 2019 | 8.40 Mn |
| Jun 30, 2019 | 17.92 Mn |
| Mar 31, 2019 | 20.43 Mn |
| Dec 31, 2018 | 24.64 Mn |
| Sep 30, 2018 | 27.09 Mn |
| Jun 30, 2018 | 17.99 Mn |
| Mar 31, 2018 | 32.34 Mn |
| Dec 31, 2017 | 18.95 Mn |
| Sep 30, 2017 | 25.49 Mn |
| Jun 30, 2017 | 13.37 Mn |
| Mar 31, 2017 | 24.19 Mn |
| Dec 31, 2016 | 14.35 Mn |
| Sep 30, 2016 | 14.10 Mn |
| Jun 30, 2016 | 16.02 Mn |
| Mar 31, 2016 | 17.24 Mn |